Viridian Therapeutics, Inc. ( NASDAQ:VRDN – Free Report ) has received a consensus recommendation of 'Buy' from the twelve research firms that are currently covering the company, Marketbeat reports. Twelve equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $45.07. Several research analysts have weighed in on the company. Wells Fargo & Company started coverage on Viridian Therapeutics in a report on Monday, April 17th.

https://www.dailypolitical.com/2023/07/09/viridian-therapeutics-inc-nasdaqvrdn-receives-consensus-rating-of-buy-from-brokerages.html

#dailypolitical